Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
Compare ALLO Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Allogene Therapeutics Inc
News & Analysis: Allogene Therapeutics Inc
The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.
ALLO earnings call for the period ending March 31, 2020.
ALLO earnings call for the period ending December 31, 2019.
ALLO earnings call for the period ending September 30, 2019.
ALLO earnings call for the period ending June 30, 2019.
ALLO earnings call for the period ending March 31, 2019.
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
Do these under-the-radar stocks deserve a spot in your growth stock portfolio?